Yıl: 2020 Cilt: 5 Sayı: 2 Sayfa Aralığı: 45 - 51 Metin Dili: İngilizce DOI: 10.4274/BMB.galenos.2020.03.07 İndeks Tarihi: 14-06-2021

Polycystic Ovary Syndrome in Overweight and Normal Weight Women: The Relationships with Inflammatory Markers

Öz:
Objective:TheetiologyandpathophysiologyofPolycysticOvarysyndrome (PCOS) are not yet clearly explained as the disease has a heterogeneous clinical presentation. Several cytokines produced by the ovary and other tissues contribute to the maintenance of a chronic inflammatory state and metabolic imbalance in PCOS. The present study aims to widen the scientific scope concerning the association between theinflammatorystateandPCOSthroughthemeasurementandevaluation of several inflammatory markers. Method: Forty-nine medication-naive PCOS patients and 39 healthy controls were enrolled in this case-control study. Blood samples were obtained for the measurement of inflammatory markers. Results: Cyclooxygenase-2 (COX-2), IL-12, IL-18, IL-23, Krüppel-like factor-4(KLF-4),peroxisomeproliferator-activatedreceptor(PPAR)-gamma, sirtuin (SIRT) and toll-like receptor-2 (TLR-2) were found to be significantly higher in the PCOS group compared to the healthy controls. There were no significant differences regarding these inflammatory markers when overweight and normal weight PCOS women were compared (p>0.05). Receiver operating characteristic curve analysis revealed that the following cut-off values had satisfactory sensitivity and specificity for the diagnosis of PCOS: 5.9 ng/mL for COX-2, 22.3 pg/mL for IL-12, 32 pg/mL for IL-18, 57 pg/mL for IL-23, 203 pg/mL for KLF-4, 2.54 ng/mL for PPAR-gamma, 2.9 ng/mL for SIRT, and 2 ng/mL for TLR-2.Conclusion: Our findings demonstrate that these inflammatory markers might be used to identify patients with PCOS with high sensitivity and specificity. Our results support the consideration that the low-grade inflammation observed in women with PCOS is likely intrinsic to the pathophysiology of the disease.
Anahtar Kelime:

Kilolu ve Normal Kadınlarda Polikistik Over Sendromunun Enflamatuvar Belirteçlerle İlişkisi

Öz:
Amaç: Polikistik Over sendromunun (PCOS) etiyolojisi ve patofizyolojisi henüz açıklanamamıştır, çünkü hastalık heterojen klinik tabloya sahiptir. Over ve diğer dokular tarafından üretilen birkaç sitokin, PCOS’de kronik birenflamatuvardurumunvemetabolikdengesizliğinkorunmasınakatkıda bulunur. Bu çalışma, çeşitli enflamatuvar belirteçlerin ölçümü ve değerlendirilmesi yoluyla enflamatuvar durum ile PCOS arasındaki ilişkiyi ve bilimsel kapsamı genişletmeyi amaçlamaktadır.Yöntem: Bu olgu-kontrol çalışmasına ilaç kullanmamış 49 PCOS hastası ve 39 sağlıklı kontrol dahil edildi. Enflamatuvar belirteçlerin ölçümü için kan örnekleri alındı. Siklooksijenaz-2 (COX-2), IL-12, IL-18, IL-23, Krüppel benzerifaktör-4,peroxisomeproliferator-activatedreceptor(PPAR)-gama, sirtuin (SIRT) ve geçiş ücreti benzeri reseptör-2 (TLR-2) ölçümleri yapıldı. Bulgular: PCOS grubunda sağlıklı kontrollere göre COX-2, IL-12, IL-18, IL-23, Krüppel benzeri faktör-4, PPAR-gama, SIRT ve TLR-2 anlamlı olarak daha yüksek bulundu. Aşırı kilolu ve normal kilolu PKOS kadınları karşılaştırıldığında bu enflamatuvar belirteçler açısından anlamlı fark yoktu(p>0,05).Alıcıişletimkarakteristiğianalizi,aşağıdakikesmedeğerlerinin PCOS tanısı için tatmin edici duyarlılığa ve özgüllüğe sahip olduğunu ortaya koymuştur: COX-2 için 5,9 ng/mL, IL-12 için 22,3 pg/mL, IL-18 için 32 pg/mL, 57 IL-23 için pg/mL, Krüppel benzeri faktör-4 için 203 pg/mL, PPAR-gama için 2,54 ng/mL, SIRT için 2,9 ng/mL ve TLR-2 için 2 ng/mL.Sonuç: Bulgularımız, bu enflamatuvar belirteçlerin PCOS’li hastaları yüksekduyarlılıkveözgüllüktetanımlamakiçinkullanılabileceğinigöstermektedir.SonuçlarımızPCOS’likadınlardagözlenendüşükdereceli enflamasyonun muhtemelen hastalığın patofizyolojisine özgü olduğu düşüncesini desteklemektedir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human reproduction 2016;31(12):2841-2855.
  • 2. Goldrat O, Delbaere A. PCOS: update and diagnostic approach. Clinical biochemistry 2018;62:24-31.
  • 3. Meier RK. Polycystic Ovary Syndrome. The Nursing clinics of North America 2018;53(3):407-420.
  • 4. Nandi A, Chen Z, Patel R, Poretsky L. Polycystic ovary syndrome. Endocrinology and metabolism clinics of North America 2014;43(1):123-147.
  • 5. Moghetti P. Insulin Resistance and Polycystic Ovary Syndrome. Current pharmaceutical design 2016;22(36):5526-5534.
  • 6. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine reviews 2016;37(5):467-520.
  • 7. Vink J, Sadrzadeh S, Lambalk C, Boomsma D. Heritability of polycystic ovary syndrome in a Dutch twin-family study. The Journal of Clinical Endocrinology & Metabolism 2006;91(6):2100-2104.
  • 8. Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction 2015;149(5):R219-R227.
  • 9. Çakıroğlu Y, Vural F, Vural B. The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes. Journal of endocrinological investigation 2016;39(8):899-907.
  • 10. Durmus U, Duran C, Ecirli S. Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters. Journal of endocrinological investigation 2017;40(5):487-497.
  • 11. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and sterility 2004;81(1):19-25.
  • 12. Ebejer K, Calleja-Agius J. The role of cytokines in polycystic ovarian syndrome. Gynecological endocrinology 2013;29(6):536-540.
  • 13. Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction 2015;149(5):R219-227.
  • 14. Xiong YL, Liang XY, Yang X, Li Y, Wei LN. Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome. European Journal of Obstetrics & Gynecology and Reproductive Biology 2011;159(1):148-150.
  • 15. Deligeoroglou E, Vrachnis N, Athanasopoulos N, Iliodromiti Z, Sifakis S, Iliodromiti S, et al. Mediators of chronic inflammation in polycystic ovarian syndrome. Gynecological Endocrinology 2012;28(12):974-978.
  • 16. Shorakae S, Teede H, de Courten B, Lambert G, Boyle J, Moran LJ. The Emerging Role of Chronic Low-Grade Inflammation in the Pathophysiology of Polycystic Ovary Syndrome. Seminars in reproductive medicine 2015;33(4):257-269.
  • 17. Dogan BA, Arduc A, Tuna MM, Karakilic E, Dagdelen I, Tutuncu Y, et al. Association of mean platelet volume with androgens and insulin resistance in nonobese patients with polycystic ovary syndrome. International journal of endocrinology and metabolism 2014;12(4):e18642.
  • 18. Cakiroglu Y, Vural F, Vural B. The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes. J Endocrinol Invest 2016;39(8):899-907.
  • 19. Ebejer K, Calleja-Agius J. The role of cytokines in polycystic ovarian syndrome. Gynecological Endocrinology 2013;29(6):536-540.
  • 20. Samy N, Hashim M, Sayed M, Said M. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Disease markers 2009;26(4):163-170.
  • 21. Barber T, Franks S. Adipocyte biology in polycystic ovary syndrome. Molecular and cellular endocrinology 2013;373(1-2):68-76.
  • 22. Zhuang XF, Zhao MM, Weng CL, Sun NL. Adipocytokines: a bridge connecting obesity and insulin resistance. Medical hypotheses 2009;73(6):981-985.
  • 23. Spaczynski RZ, Arici A, Duleba AJ. Tumor necrosis factor-α stimulates proliferation of rat ovarian theca-interstitial cells. Biology of Reproduction 1999;61(4):993-998.
  • 24. Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril 2011;95(3):1048-1058.
  • 25. Sathyapalan T, Kilpatrick ES, Coady A-M, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. The Journal of Clinical Endocrinology & Metabolism 2009;94(1):103-108.
  • 26. Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. The Journal of Clinical Endocrinology & Metabolism 2009;94(12):4938-4945.
  • 27. Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators of inflammation 2010;2010:758656.
  • 28. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Human Reproduction 2001;16(6):1255-1260.
APA ATAKUL T, TURAN O, Yenisey Ç (2020). Polycystic Ovary Syndrome in Overweight and Normal Weight Women: The Relationships with Inflammatory Markers. , 45 - 51. 10.4274/BMB.galenos.2020.03.07
Chicago ATAKUL TOLGA,TURAN OZGÜR DENIZ,Yenisey Çiğdem Polycystic Ovary Syndrome in Overweight and Normal Weight Women: The Relationships with Inflammatory Markers. (2020): 45 - 51. 10.4274/BMB.galenos.2020.03.07
MLA ATAKUL TOLGA,TURAN OZGÜR DENIZ,Yenisey Çiğdem Polycystic Ovary Syndrome in Overweight and Normal Weight Women: The Relationships with Inflammatory Markers. , 2020, ss.45 - 51. 10.4274/BMB.galenos.2020.03.07
AMA ATAKUL T,TURAN O,Yenisey Ç Polycystic Ovary Syndrome in Overweight and Normal Weight Women: The Relationships with Inflammatory Markers. . 2020; 45 - 51. 10.4274/BMB.galenos.2020.03.07
Vancouver ATAKUL T,TURAN O,Yenisey Ç Polycystic Ovary Syndrome in Overweight and Normal Weight Women: The Relationships with Inflammatory Markers. . 2020; 45 - 51. 10.4274/BMB.galenos.2020.03.07
IEEE ATAKUL T,TURAN O,Yenisey Ç "Polycystic Ovary Syndrome in Overweight and Normal Weight Women: The Relationships with Inflammatory Markers." , ss.45 - 51, 2020. 10.4274/BMB.galenos.2020.03.07
ISNAD ATAKUL, TOLGA vd. "Polycystic Ovary Syndrome in Overweight and Normal Weight Women: The Relationships with Inflammatory Markers". (2020), 45-51. https://doi.org/10.4274/BMB.galenos.2020.03.07
APA ATAKUL T, TURAN O, Yenisey Ç (2020). Polycystic Ovary Syndrome in Overweight and Normal Weight Women: The Relationships with Inflammatory Markers. Bağcılar Tıp Bülteni, 5(2), 45 - 51. 10.4274/BMB.galenos.2020.03.07
Chicago ATAKUL TOLGA,TURAN OZGÜR DENIZ,Yenisey Çiğdem Polycystic Ovary Syndrome in Overweight and Normal Weight Women: The Relationships with Inflammatory Markers. Bağcılar Tıp Bülteni 5, no.2 (2020): 45 - 51. 10.4274/BMB.galenos.2020.03.07
MLA ATAKUL TOLGA,TURAN OZGÜR DENIZ,Yenisey Çiğdem Polycystic Ovary Syndrome in Overweight and Normal Weight Women: The Relationships with Inflammatory Markers. Bağcılar Tıp Bülteni, vol.5, no.2, 2020, ss.45 - 51. 10.4274/BMB.galenos.2020.03.07
AMA ATAKUL T,TURAN O,Yenisey Ç Polycystic Ovary Syndrome in Overweight and Normal Weight Women: The Relationships with Inflammatory Markers. Bağcılar Tıp Bülteni. 2020; 5(2): 45 - 51. 10.4274/BMB.galenos.2020.03.07
Vancouver ATAKUL T,TURAN O,Yenisey Ç Polycystic Ovary Syndrome in Overweight and Normal Weight Women: The Relationships with Inflammatory Markers. Bağcılar Tıp Bülteni. 2020; 5(2): 45 - 51. 10.4274/BMB.galenos.2020.03.07
IEEE ATAKUL T,TURAN O,Yenisey Ç "Polycystic Ovary Syndrome in Overweight and Normal Weight Women: The Relationships with Inflammatory Markers." Bağcılar Tıp Bülteni, 5, ss.45 - 51, 2020. 10.4274/BMB.galenos.2020.03.07
ISNAD ATAKUL, TOLGA vd. "Polycystic Ovary Syndrome in Overweight and Normal Weight Women: The Relationships with Inflammatory Markers". Bağcılar Tıp Bülteni 5/2 (2020), 45-51. https://doi.org/10.4274/BMB.galenos.2020.03.07